-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zifanocycline in Community-Acquired Bacterial Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zifanocycline in Community-Acquired Bacterial Pneumonia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zifanocycline in Community-Acquired Bacterial Pneumonia Drug Details: Zifanocycline (KBP-7072) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cisplatin + Vinblastine Sulphate) in Thyroid Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cisplatin + Vinblastine Sulphate) in Thyroid Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cisplatin + Vinblastine Sulphate) in Thyroid Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MAX-4 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MAX-4 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MAX-4 in Metastatic Colorectal Cancer Drug Details: MAX-4 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Muscle Invasive Bladder Cancer (MIBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Muscle Invasive Bladder Cancer (MIBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Muscle Invasive Bladder Cancer (MIBC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Urethral Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Urethral Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Urethral Cancer Drug Details: Tislelizumab (Baizean, Tevimbra) is a...
-
Product Insights
Alopecia Areata – Drugs In Development, 2023
Global Markets Direct’s, ‘Alopecia Areata - Drugs In Development, 2023’, provides an overview of the Alopecia Areata pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia Areata, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Alopecia – Drugs In Development, 2023
Global Markets Direct’s, ‘Alopecia - Drugs In Development, 2023’, provides an overview of the Alopecia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Max-5 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Max-5 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Max-5 in Solid Tumor Drug Details: Max-5 is under development of the...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Max-1 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Max-1 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Max-1 in Solid Tumor Drug Details: Max-1 is under development for the...